Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q1 2017 · 10-Q
Revenue$29.57M$29.57M−30.4% vs Q1 2016 Net Income-$32.90M-$32.90MN/M vs Q1 2016 EPS Diluted-$260.00-$260.00N/M vs Q1 2016 Gross Profit$3,890,000−24.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flow-$22,459,000N/M Free Cash Flowderived-$22,558,000N/M Margins · derivedGross margin13.2%+1.0 pt vs Q1 2016
Operating margin-93.1%−55.0 pt vs Q1 2016
Net margin-111.3%−64.6 pt vs Q1 2016
ended Mar 31, 2017 · filed May 9, 2017 · 39 d after period end